story of the week
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
N. Engl. J. Med 2019 Sep 30;[EPub Ahead of Print], S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, H Wasan, F Ciardiello, F Loupakis, YS Hong, N Steeghs, TK Guren, HT Arkenau, P Garcia-Alfonso, P Pfeiffer, S Orlov, S Lonardi, E Elez, TW Kim, JHM Schellens, C Guo, A Krishnan, J Dekervel, V Morris, A Calvo Ferrandiz, LS Tarpgaard, M Braun, A Gollerkeri, C Keir, K Maharry, M Pickard, J Christy-Bittel, L Anderson, V Sandor, J TaberneroFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.